AI Article Synopsis
- Hidradenitis suppurativa (HS) is a long-term skin disease that's tough to manage and treat.
- Biologics and small targeted molecules are being explored as potential treatments for moderate-to-severe HS, with only three approved by FDA or EMA: adalimumab, secukinumab, and bimekizumab.
- Ongoing research is focusing on new agents that target various inflammatory pathways, including interleukin 17A/F and the JAK/STAT pathway.
Article Abstract
Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that can be challenging to treat. Biologics and targeted small molecules have become an increasingly popular area of investigation for therapeutic development for moderate-to-severe HS, though only three biologics-adalimumab, secukinumab, and bimekizumab-have received US Food and Drug Administration (FDA) or European Medicines Evaluation Agency approval for treating HS. Promising agents under investigation are targeting interleukin 17A/F, JAK/STAT pathway, interleukin 36, interleukin 1, and more.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40257-024-00880-1 | DOI Listing |
Publication Analysis
Top Keywords
hidradenitis suppurativa
8
suppurativa targets
4
targets emerging
4
emerging treatments
4
treatments hidradenitis
4
suppurativa chronic
4
chronic inflammatory
4
inflammatory skin
4
skin condition
4
condition challenging
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!